TC011

TC011 is a CAR-T cell therapy developed by TICAROS. Its target is CD19 (the sponsor names CD19). The sponsor states: TC011 is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, given after fludarabine/cyclophosphamide lymphodepleting chemotherapy, for relapsed/refractory large B-cell non-Hodgkin lymphoma. ClinicalTrials.gov describes the intervention as: Anti-CD19 Chimeric Antigen Receptor T cell. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma and follicular lymphoma. The largest, NCT07473167, plans to enrol 98 participants with primary completion expected 2028-02-11. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.